Key facts
- · Type: Amendment first sale 2026-05-14 · Amount sold: $9.25M · Total offering: $10M · SEC filing
- · Type: New offering first sale 2026-05-14 · Amount sold: $1.45M · Total offering: $8M · SEC filing
- · Type: New offering first sale 2025-06-26 · Amount sold: $6.36M · Total offering: $7M · SEC filing
- · Type: Amendment first sale 2023-10-19 · Amount sold: $7.98M · Total offering: $12.50M · SEC filing
- · Type: New offering first sale 2023-10-19 · Amount sold: $4.55M · Total offering: $10M · SEC filing
Is Reprise Biomedical, Inc. a real, registered company?
Reprise Biomedical, Inc. is a registered filer with the SEC (CIK 1782236) and has filed since 2023-01-03. 7 filings are on record, the latest on 2026-07-01.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Who runs Reprise Biomedical, Inc.?
Reprise Biomedical, Inc.'s filings name Carrie Powers, Erwin Kelen, Howard Root and 12 more as its officers, directors or promoters.
How much has Reprise Biomedical, Inc. raised?
Its new offerings report $25.40M sold across 4 offerings, as its own filings state.
Run the free check on Reprise Biomedical, Inc. →
Plymouth, MINNESOTA
Biotechnology
7
$25.40M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-07-01 | Amendment first sale 2026-05-14 | $9.25M | $10M | SEC filing |
| 2026-05-21 | New offering first sale 2026-05-14 | $1.45M | $8M | details · SEC filing |
| 2025-07-11 | New offering first sale 2025-06-26 | $6.36M | $7M | details · SEC filing |
| 2023-12-13 | Amendment first sale 2023-10-19 | $7.98M | $12.50M | SEC filing |
| 2023-11-02 | New offering first sale 2023-10-19 | $4.55M | $10M | SEC filing |
| 2023-01-25 | Amendment first sale 2022-12-20 | $15.30M | $15.30M | SEC filing |
| 2023-01-03 | New offering first sale 2022-12-20 | $13.04M | $14.80M | SEC filing |
Want the whole picture on Reprise Biomedical, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Reprise Biomedical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Reprise Biomedical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Reprise Biomedical, Inc.'s own filings with the SEC. The people those filings name are on the team page.